Law360, New York (April 29, 2010, 5:52 PM ET) -- A unit of Johnson & Johnson has agreed to pay more than $81 million to put to rest a U.S. Department of Justice inquiry into off-label marketing of the epilepsy and migraine drug Topamax.
Under the agreement reached with the DOJ and other federal agencies, Ortho-McNeil-Janssen Pharmaceuticals Inc. will pay $75.37 million to settle allegations that the company improperly marketed Topamax for off-label psychiatric uses, causing false claims to be submitted to government health care programs such as Medicaid that do not cover those uses of...
J&J Unit Settles Off-Label Marketing Claims For $81M
To view the full article, take a free trial now.
